MedTrace Logo

Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting

NCT05266495 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2025-01-13

No results posted yet for this study

Summary

The study is a prospective and retrospective, observational, single-arm, non-randomized cohort study of ocular treatment with intravitreal injections of brolucizumab in nAMD patients. This study will be conducted prospectively and retrospectively (for patients who had their first brolucizumab injection before study start) using data collected in a standardized manner.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

OTHER

Brolucizumab

There is no treatment allocation. Patients administered brolucizumab by prescription will be enrolled.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-13
Primary Completion
2023-03-13
Completion
2023-03-13

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05266495 on ClinicalTrials.gov